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2 
ABSTRACT 41 
Context: Few studies directly compare amygdala function in depressive and anxiety disorders. 42 
Data from longitudinal research emphasize the need for such studies in adolescents.  43 
Objective: To compare amygdala response to varying attention and emotion conditions among 44 
adolescents with Major Depressive Disorder (MDD) or anxiety disorders, relative to adolescents 45 
with no psychopathology. 46 
Design: Case-Control-Study. 47 
Setting: Government Clinical Research Institute. 48 
Participants: Eighty-seven adolescents matched on age, gender, intelligence, and social class: 26 49 
with Major Depressive Disorder (MDD; 14 with and 12 without anxiety disorders), 16 with 50 
anxiety disorders but no depression, and 45 with no psychopathology.  51 
Main Outcome Measures: Blood oxygenated level dependent signal in the amygdala, measured 52 
using event-related functional magnetic resonance imaging. During imaging, participants viewed 53 
facial expressions (neutral, fearful, angry, happy) while attention was constrained (afraid, 54 
hostility, nose width ratings) or unconstrained (passive-viewing).  55 
Results: Left and right amygdala activation differed as a function of diagnosis, facial expression, 56 
and attention-condition both when comorbid MDD/anxiety patients were included and excluded 57 
(group-by-emotion-by-attention interactions: p-values≤.03). Focusing on fearful-face-viewing 58 
events, anxiety and MDD patients both differed in amygdala responses from healthy participants 59 
and from each other during passive-viewing. However, both MDD and anxiety patients, relative 60 
to healthy participants, exhibited similar signs of amygdala hyper-activation to fearful faces when 61 
rating subjectively experienced fear. 62 
Conclusions: Adolescent MDD and anxiety disorders exhibit common and distinct functional 63 
neural correlates during face processing. Attention modulates the degree to which common or 64 
distinct amygdala perturbations manifest in these patient groups, relative to healthy peers. 65 
66 
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INTRODUCTION 67 
 Rates of anxiety and depression markedly increase in adolescence.
1,2
 Comorbidity data
3-10
 68 
suggest that these conditions may share brain-based diatheses.
11-13
 However, non-comorbid cases 69 
of anxiety and depression
2,10,14
 raise questions about neural differences. In adults, biased 70 
amygdala engagement occurs in major depressive disorder (MDD)
15-18
 and anxiety disorders.
19-24
 71 
For both conditions, increased amygdala activation has been reliably seen, suggesting shared 72 
neural-circuitry dysfunction. However, strong conclusions cannot be drawn, since few studies 73 
directly contrast patient groups with each other and with healthy individuals.    74 
 Vital questions emerge on commonalities and distinctions between adolescent MDD and 75 
anxiety disorders. Work is important in this age group, since most adult mood and anxiety 76 
disorders are preceded by adolescent disorders.
5,6
 Similar functional perturbations could present 77 
in adolescent and adult mood and anxiety disorders; alternatively, unique perturbations could 78 
present in adolescence that ultimately evolve into adult profiles. Studies of adolescents begin to 79 
consider these possibilities by charting early-emerging correlates of mood and anxiety disorders.  80 
Since anxiety disorders differ from MDD in several ways,
1,2,10,25,26
 specific neural correlates may 81 
be expected. Nevertheless, few neuroimaging studies compare adequately-sized samples of MDD 82 
and anxiety-disorder patients at any age, and studies in adolescents appear especially rare. As in 83 
adults, initial findings in anxious adolescents
27-30
 and in individuals at risk for anxiety disorders
31
 84 
show altered amygdala function relative to healthy subjects, with signs of enhanced activation to 85 
fear-faces.
27,28,31
 86 
 To our knowledge, only two studies examined amygdala response to facial stimuli in 87 
adolescent MDD.
28,29
 Their results are inconsistent, with one study finding increased
29
 and the 88 
other decreased
28
 amygdala activity relative to healthy participants. Findings from two other 89 
studies
32,33
 suggest that biased amygdala function in individuals at risk for MDD occurs 90 
specifically when passively viewing emotional stimuli. Because neither study excluded subjects 91 
with anxiety disorders, the influence of anxiety remains unclear.  92 
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 The primary goal of the current study is to compare amygdala engagement to face-93 
emotion stimuli among three groups of adolescents: MDD patients, anxiety patients, and healthy 94 
subjects. Comparative analyses require “pure” groups, but prior research in adolescent 95 
MDD
28,29,33,34
 includes anxious individuals. Thus, we study MDD patients both with comorbid 96 
anxiety included and excluded. Existing data support competing hypotheses. On the one hand, 97 
data in adults,
16-21,24
 together with the strong cross-sectional, longitudinal, and familial 98 
relationships among adolescent and adult anxiety and MDD,
3-10,14
 raise the expectation of 99 
overlapping amygdala dysfunction, consistent with a “shared diathesis” perspective.11,12 Based on 100 
these data, one might expect similarly biased amygdala engagement in anxious and MDD 101 
adolescents, relative to healthy peers. On the other hand, preliminary data suggest that amygdala 102 
engagement in anxious and MDD adolescents might vary with changing emotional state and 103 
attention,
27,31-33
 consistent with evidence of disorder-specific cognitive biases.
13,35,36
 104 
  105 
METHODS 106 
PARTICIPANTS 107 
 Eighty-seven adolescents were studied: 26 with MDD, 16 non-MDD with anxiety 108 
disorders, and 45 without psychopathology. MDD patients were initially recruited; others were 109 
then selected from larger pools to form three groups, matched on age, sex, social class, and IQ 110 
(Table 1). While groups did not differ statistically on these variables, anxiety patients included 111 
somewhat younger and more male subjects; we repeated all analyses covarying for age and sex. 112 
A prior report
27
 included 7 of the 16 anxiety and 16 of the 45 healthy adolescents.  113 
(Table 1) 114 
Diagnoses were assessed using the Schedule-for-Affective-Disorders-and-Schizophrenia-115 
for-School-Aged-Children (K-SADS).
37
 As described previously,
27,29
 MDD and anxiety patients 116 
were required i) to show persistent, impairing anxiety or depressive symptoms, respectively, 117 
during three weeks of supportive therapy, and ii) to meet previously-reported exclusion criteria.  118 
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All anxiety patients were without lifetime history of MDD; all non-anxious MDD patients were 119 
without lifetime history of anxiety. All were medication-free, and only one had past exposure to 120 
any anxiolytic, such as an SSRI. The study was approved by the NIMH-IRB. All 121 
participants/parents provided written informed consent/assent. 122 
TASK 123 
 We used functional magnetic resonance imaging (fMRI) with a previously-described 124 
paradigm.
27,29,31,38
 Briefly, participants viewed 32 faces (8 each of: neutral, fearful, angry, 125 
happy),
39-41
 each presented for 4000 ms, four times in one 160-trial run, divided into four 40-trial 126 
epochs (32 faces, 8 fixation trials) and four ten-trial blocks (8 faces, 2 fixation trials). During 127 
three blocks, participants adopted different constrained attention states by rating the face stimuli 128 
on 5-point scales (1=not at all to 5=very): (1) “How hostile is this face?”, (2) “How afraid are you 129 
of this face?”, and (3) “How wide is the nose?”. During the fourth block, participants passively 130 
viewed the faces (unconstrained attention). Order of face presentation and attention-conditions 131 
were randomized. Ratings and reaction times (RTs) were recorded.   132 
 133 
MRI PROCEDURES 134 
 Whole-brain blood-oxygen-level-dependent (BOLD) fMRI data were acquired on one of 135 
two 3-T scanners in groups matched with regard to scanner (χ2=4.05, df=2, p=.13). T2-weighted 136 
images were acquired in 23 axial slices parallel to the anterior-commissure/posterior-commissure 137 
line using an echo-planar single-shot gradient echo pulse sequence (matrix=64x64; repetition 138 
time (TR)=2000 milliseconds; echo time (TE)=40 milliseconds; field of view (FOV)=240 mm; 139 
voxels=3.75x3.75x5.0 mm). As reported previously,
27,29
 high-resolution T1-weighted anatomical 140 
images were acquired. 141 
   Data from subjects moving >2.5 mm in any plane were discarded. Subsequent analyses were 142 
conducted with SPM99 and Matlab 6.1 routines. Functional data were corrected for slice timing 143 
and motion, anatomically co-registered, and spatially normalized to the SPM99 Montreal 144 
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Neurologic Institute (MNI) T1-weighted template. We used SPM99 to maximize parallels with 145 
prior work.
27,31,42
 Nevertheless, group analyses implemented in SPSS15.0 avoid problems created 146 
by outdated aspects of SPM99.  147 
DATA ANALYSIS 148 
Behavioral Data 149 
 Ratings and RTs confirm participants’ task compliance and evaluate group differences 150 
in behavior. Due to an equipment malfunction, data for three participants were not recorded. Data 151 
were analyzed with analyses of variance (ANOVAs) with diagnostic group as the between-152 
subjects factor and face-emotion and attention-condition as within-subjects factors. To minimize 153 
Type-I errors the Greenhouse-Geisser correction was applied.
43
 154 
 155 
fMRI Data 156 
 We estimated event-related-response amplitudes at the individual-subject level for each 157 
face-emotion type in each attention-condition using the General Linear Model (GLM). The 158 
waveform for each event-related response was a rectangular pulse (4 seconds) convolved with the 159 
SPM99 hemodynamic response function (HRF). We generated contrast images using pair-wise 160 
comparisons across event types. We then divided each contrast image by subject-specific voxel 161 
time series means.
44
  162 
 Group-level analyses use random effects models.
45
 Prior findings document amygdala 163 
abnormalities on this task in pediatric anxiety
27
 and bipolar
42
 disorder. Hence, we used a region-164 
of-interest (ROI) strategy focused on the amygdala, defined using standard criteria
46
 on the MNI 165 
template. All subjects had BOLD activity data in >65% of ROI voxels. BOLD signal changes for 166 
each event vs. fixation baseline were averaged across all amygdala voxels and were submitted in 167 
SPSS15.0 to multi-factorial analyses of complex two- and-three-way interactions. 168 
 Our primary hypothesis was that overall between-group amygdala differences vary as a 169 
function of both face-emotion type and attention. We tested this with omnibus three-way group-170 
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by-face-emotion-by-attention-condition interactions, in repeated-measures ANOVAs for each 171 
amygdala, with one 3-level between-subject factor (group) and two 4-level within-subject factors 172 
(emotion, attention). Two analyses were conducted, using Greenhouse-Geisser correction: (1) 173 
including 14 comorbid anxiety patients in the MDD group (n=26) and (2) including only non-174 
comorbid MDD cases (n=12). Focused post-hoc analyses decomposed significant three-way 175 
interactions. These post-hoc analyses compared amygdala activation (1) to fearful faces 176 
specifically viewed across different attention-conditions and (2) across all face-types specifically 177 
in the passive-viewing condition. This post-hoc approach extends prior findings.   178 
 Data from three studies in anxiety patients,
27
 youths at risk for anxiety,
31
 or at risk for 179 
depression
33
 had led us to expect between-group differences to fearful faces, specifically, relative 180 
to other face-types, viewed in particular attention-conditions: we expected hyper-activation in 181 
anxiety when participants monitored subjective fear, relative to passively viewing fear-faces.  182 
This prediction was first investigated by a two-factor repeated-measure ANOVA testing the 183 
significance of group-by-attention-condition interactions for amygdala activation to fearful faces, 184 
relative to fixation, across all four attention-conditions. This was followed by three-group 185 
ANOVAs (Brown-Forsythe test when variances unequal) and two-group t-tests for the a-priori-186 
defined “fearful-afraid-vs.-fearful-passive” contrast.   187 
 Prior research also suggested that specific anxiety-related and depression-related biases 188 
manifest during passive-viewing.
27,28,31,33
 Based on McClure et al.
27
, Pérez-Edgar et al.
31
 and 189 
Monk et al.
33
, we expected greater amygdala activation to fearful faces passively viewed in MDD 190 
than anxious and healthy individuals. However, prior studies generate inconsistent data 191 
concerning amygdala response to other face-emotion types, viewed passively. Thus, we 192 
performed a two-factor repeated-measure ANOVA including all face-emotion classes to test the 193 
significance of a group-by-face-emotion interaction in passive-viewing; post-hoc tests focused on 194 
contrasts of fearful versus other emotions. 195 
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  Finally, although the current study focused on the amygdala, secondary analyses 196 
examined the orbitofrontal cortex (OFC), guided by previous research.
15,16,20,27,34,47-49
 Procedures 197 
followed those for the amygdala by extracting values for entire ROIs,
27,29
 defined using standard, 198 
validated anatomical criteria, as delineated in previous research.
46
 Of note, the OFC ROI used 199 
here encompasses both medial and lateral inferior-frontal expanses of prefrontal cortex (PFC).  200 
Due to susceptibility-related signal loss, two individuals were excluded, yielding n=26 MDD, 201 
n=15 anxiety, and n=44 healthy adolescents. 202 
 In addition to ROI analyses, supplementary voxel-based techniques generated coordinates 203 
of between-group peak-activation differences. As we entered this work with relatively clear, 204 
regionally-based, a priori hypotheses and we wanted to minimize Type-II-errors in this three-205 
group study, we treated results from our ROI-based analyses as primary. Nevertheless, findings 206 
from voxel-based analyses replicated those in whole-structure ROI approaches while also 207 
informing future work; they are accordingly summarized using MNI coordinates. 208 
 209 
RESULTS 210 
SAMPLE CHARACTERISTICS & BEHAVIOR 211 
          Table 1 displays sample demographic and clinical characteristics; Table 2 displays 212 
behavioral performance during scanning. These behavioral data revealed the expected face-213 
emotion-by-attention-condition interactions for ratings (F[4.6,368.6]=63.6; p<.001) and RTs 214 
(F[5.5,446.9]=15.4; p<.001). Both ratings and RTs for the “afraid” and “hostile” questions were 215 
highest for angry and fearful faces and lowest for happy faces; “nose” ratings and RTs were 216 
highest for happy and angry faces and lowest for neutral faces. No two- or three-way interactions 217 
with group were found for either ratings or RTs (p=.15-to-=.76). No significant main-effects of 218 
group emerged on ratings (F[2,81]=1.2; p=.32) or RTs (F[2,81]=1.6; p=.20). Similar findings 219 
were revealed when excluding comorbid MDD/anxiety patients [available upon request].  220 
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Absence of group-effects indicates that all groups similarly altered behavior across emotion and 221 
attention-conditions.  222 
(Table 2) 223 
 224 
IMAGING 225 
Amygdala activation 226 
 We tested our primary hypothesis using repeated-measures ANOVAs for BOLD 227 
responses in each amygdala. These analyses revealed the expected three-way group-by-face-228 
emotion-by-attention-condition interaction in left and in right amygdalae (Table 3). 229 
(Table 3) 230 
 Three-way interactions indicate that between-group differences vary with both face-231 
emotion and attention-condition. These were decomposed in post-hoc tests focusing on a-priori 232 
anticipated group-differences. Specifically, differences were expected (1) in select attention-233 
conditions in fearful-face viewing events and (2) when fearful faces versus other face-emotions 234 
were passively viewed.  235 
 236 
Fearful-face viewing.   237 
 Based on prior research,
27,31,33
 we predicted between-group differences in amygdala 238 
response to fearful faces with hyper-activation in anxiety patients during afraid ratings. As 239 
expected, significant bilateral group-by-attention-condition interactions emerged when comorbid 240 
MDD/anxiety patients were included (left: F[5.8,244.0]=6.4, p<.001, Figure 1a; right: 241 
F[5.5,231.0]=2.5, p=.03) or excluded (left: F[5.6,197.8]=6.1, p<.001; right: F[5.3,185.9]=2.3, 242 
p=.05). Anxiety patients showed the predicted amygdala hyper-activation when rating 243 
subjectively-experienced fear to fearful faces but not when passively viewing these faces.  244 
 In the a-priori defined “fearful-afraid-vs.-fearful-passive” contrast, significant between-245 
group differences were evident only in left amygdala (comorbid MDD/anxiety patients included: 246 
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F[2,25.8]=4.7; p=.02, Figure 1b; comorbid MDD/anxiety patients excluded: F[2,25.6]=5.3, 247 
p=.01; Figure 1c). Data from this contrast supported the “shared-diathesis” perspective. Thus, 248 
both anxiety (t18.5=2.2, p=.04; see also Figure 1d) and MDD (with and without anxiety: t69=3.2; 249 
p=.002; without anxiety: t55=3.2; p=.002, see also Figure 1e) patients showed greater amygdala 250 
activation than healthy peers, with no significant differences between patient groups.   251 
(Figure 1) 252 
 We also compared groups on other “fearful-face” contrasts (e.g., afraid-nose, hostile-nose; 253 
compare Figure 1a). This revealed consistent evidence of increased activation in anxious, relative 254 
to healthy subjects, somewhat less consistent evidence of enhanced activation in MDD, relative 255 
to healthy subjects, and in anxiety patients relative to MDD patients (results available on request). 256 
Further analyses did reveal between-group differences during afraid-rating to show some degree 257 
of emotion-specificity: no between-group differences emerged for afraid-rating events with 258 
neutral or happy faces (p-values>.35).   259 
 260 
Passive-viewing.  261 
 As noted previously, prior studies most consistently yielded disorder-specific biases under 262 
unconstrained attention-conditions.
27,28,31,33
  Thus, we were particularly interested in between-263 
group comparisons in this condition. Across passive-viewing face-types, significant group-by-264 
face-emotion interactions emerged in left (F[5.5,230.3]=3.2, p=.006; Figure 2a) and right 265 
(F[5.4,226.8]=3.2, p=.04) amygdala. Similar results occurred when excluding comorbid 266 
MDD/anxiety cases (left: F[5.4,188.1]=3.4, p=.005; right: F[5.3,186.1]=2.2, p=.05).    267 
 Post-hoc tests focused on fearful versus other face-emotions, as prior research did not 268 
generate more specific hypothesis. The interactions reflected amygdala activation differences for 269 
the “fearful-passive-vs.-happy-passive” contrast, both when comorbid MDD/anxiety patients 270 
were included (left: F[2,84]=6.6, p=.002, Figure 2b; right: F[2,84]=5.1, p=.008) or excluded (left: 271 
F[2,70]=6.5; p=.003, Figure 2c; right: F[2,70]=4.6, p=.01). Consistent with the “disorder-272 
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specificity” perspective, opposite patterns emerged in patient groups: anxiety patients showed 273 
activation and MDD patients showed deactivation for fearful versus happy faces. This difference 274 
was significant whether MDD/anxiety patients were included (left: t40=3.3, p=.002, Fig. 2b; right: 275 
t40=2.8, p=.008) or excluded (left: t26=3.1, p=.004, Fig. 2c; right: t26=2.4, p=.02). Both patient 276 
groups also showed significantly different responses from healthy controls, with hyper-activation 277 
in anxiety (left: t59=2.2, p=.03; right: t59=2.6, p=.01) and hypo-activation in MDD (left only: with 278 
or without comorbid anxiety disorder: t69=-2.2, p=.03; without comorbid anxiety disorder: t55=-279 
2.4, p=.02). 280 
(Figure 2) 281 
 Of note, post-hoc results also showed that between-group differences reflected responses 282 
to “passive-happy” events, independent of the response to “fear-faces”. Comparing groups on the 283 
“neutral-passive”-vs.-“happy-passive” contrast revealed amygdala hyper-activation in anxiety, 284 
relative to both healthy and MDD subjects, similar to the “fearful-passive”-vs.-“happy-passive” 285 
contrast. However, healthy and MDD subjects did not differ (p-values=.09). Further analyses 286 
demonstrated the between-group differences for happy faces to be specific to passive-viewing: no 287 
between-group differences emerged during afraid- or hostility-ratings (p-values>=.37). Finally, 288 
we repeated all analyses using amygdala ROIs while covarying for age and sex. No differences in 289 
results occurred (available upon request).  290 
 291 
OFC activation 292 
 Secondary analyses examined group differences in OFC in the a-priori defined “fearful-293 
afraid-vs.-fearful-passive” contrast. Results were largely consistent with those emerging in the 294 
amygdala-based analyses, both when comorbid MDD/anxiety patients were included (left OFC: 295 
F[2,82]=3.2, p=.05, Figure 3a) or excluded (left OFC: F[2,68]=2.7, p=.08, Figure 3b). Anxiety 296 
patients showed significantly enhanced left OFC activation relative to healthy subjects (t57=2.2, 297 
p=.04; Figure 3c); a non-significant trend emerged for the MDD vs. healthy comparison, but only 298 
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when comorbid MDD/anxiety patients were included (t68=1.8, p=.07). No significant differences 299 
emerged between the anxiety and the MDD groups. 300 
 (Figure 3) 301 
  We also examined group differences in the “fearful-passive-vs.-happy-passive” contrast 302 
that evidenced “disorder-specificity” in amygdala response. Between-group differences were also 303 
found in the right OFC, both when comorbid MDD/anxiety patients were included F[2,82]=4.2, 304 
p=.02, Figure 4a) or excluded F[2,68]=5.3, p=.007, Figure 4b). Anxiety patients showed 305 
significantly greater activation than MDD patients (with and without comorbid anxiety: t39=2.1, 306 
p=.04; without comorbid anxiety: t25=2.5, p=.02) and than healthy controls (t57=3.2, p=.002). 307 
MDD patients, however, did not differ from healthy controls.  308 
(Figure 4) 309 
 Repeating the OFC-related analyses covarying for age and sex did not change the results 310 
with one exception. The significance of the difference between anxiety and MDD patients in the 311 
“fearful-passive-vs.-happy-passive” contrast was diminished when comorbid MDD/anxiety 312 
patients were included (F[1,37]=2.8, p=.10), but not when considering MDD alone (F[1,23]=5.1, 313 
p=.03). 314 
 315 
COMMENT 316 
 The current study generates two key findings. First, when adolescents viewed faces 317 
expressing fear and focused their attention on internally experienced fear, relative to passive 318 
viewing, both anxiety and MDD patients exhibited greater amygdala activation than healthy 319 
peers. Second, distinct emotion-specific amygdala responses in MDD and anxiety disorders 320 
occurred during passive viewing, where patients also significantly differed from healthy peers.  321 
 The degree to which MDD and anxiety disorders represent nosologically distinct 322 
conditions remains unclear. Particularly intense debate occurs regarding youth. This arises in 323 
light of longitudinal data demonstrating strong but relatively non-specific associations over time 324 
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among MDD and anxiety disorders in adolescents and in adults.
5,6,50,51
 The current data suggest 325 
that adolescent anxiety disorders and MDD exhibit neural commonalities but also demonstrable 326 
differences, depending on the specific attention and emotion states engaged during fMRI. From a 327 
theoretical perspective, this suggests that adolescent anxiety disorders and MDD involve 328 
complex, overlapping yet distinguishable patterns of amygdala-related biases. For some biases, 329 
related to subjective-state monitoring, similar perturbation of amygdala engagement and 330 
associated psychological processes may occur in MDD and anxiety. For other, spontaneously-331 
elicited psychological processes engaged during unconstrained, passive viewing of faces, 332 
disorder-specific biasing may occur. Viewed broadly, these data support the view of neural 333 
distinctions between MDD and anxiety as complex and nuanced but clearly demonstrable.        334 
 335 
Disorder-Specificity 336 
 Our study finds evidence of specifically perturbed amygdala engagement in adolescent 337 
MDD and anxiety disorders, manifest in select attention states for specific face-emotions. This 338 
conclusion emerges from our omnibus approach to between-group contrasts. Such a statistical 339 
approach is necessarily complex: it rests on tests of three-way, group-by-emotion-by-attention 340 
interactions. Significant interactions emerge because between-group differences in anxious and 341 
MDD adolescents occur only when viewing fearful versus happy faces passively but not when 342 
viewing other emotions or when viewing these same emotions in other attention states.   343 
 Disorder-specificity was expected during passive-viewing, given prior research.
27,28,31,33
  344 
However, differences between the current and these prior studies complicate cross-study 345 
comparisons. These differences encompass clinical features of samples, task-stimulus features, 346 
and task-related cognitive processes. Nevertheless, the finding that disorder-specificity emerges 347 
during passive-viewing is consistent with other work.
27,28,31,33
 This suggests that disorder-specific 348 
findings emerge when subjects are allowed to engage information processing strategies elicited 349 
naturally, during passive-viewing, an instance where task instructions do not constrain attention.  350 
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Further work is needed specifying the precise psychological nature of these disorder-specific 351 
processes that may emerge spontaneously.      352 
 Despite consistency across the current and prior studies, questions remain. For example, 353 
both Monk et al.
33
 and the current study revealed MDD-related between-group differences in 354 
amygdala response during passive-viewing; however, Monk et al. found amygdala hyper-355 
activation in at-risk adolescents viewing morphed faces showing varying blends of fear; the 356 
current study found amygdala hypo-activation in MDD-affected subjects viewing faces showing 357 
full displays of fear. Thus, these inconsistencies may be due to methodological differences.  358 
 Other questions emerge related to developmental perspectives. Due to strong longitudinal 359 
and family-based aggregation among MDD and anxiety disorders manifest in adolescents and 360 
adults,
3-10,14
 one might expect brain imaging findings in adult MDD and anxiety
16-21,24
 to parallel 361 
the findings observed here, in adolescents. Nevertheless, few imaging studies contrast anxious 362 
and MDD adults with any paradigm; none use paradigms similar to the one used here, which 363 
shows that different conclusions emerge concerning between-group comparisons as a function of 364 
relatively subtle task-related features. As with inconsistencies in work with adolescents, the 365 
dearth of studies directly comparing anxious and MDD adults emphasizes the need for more 366 
research on the nature of perturbed amygdala engagement in risk for and expression of MDD and 367 
anxiety. In pursuing such work, the current findings highlight the need to consider the sensitivity 368 
of group differences to variations in attention-conditions across fMRI paradigms.  369 
 One finding calls for particular attention. MDD-related deactivation specifically to 370 
passively-viewed happy faces represents a major contributor to the disorder-specific between-371 
group differences in the “fearful-passive-vs.-happy-passive” contrast. Given the tendency in prior 372 
research to focus on hyper-activation, this finding for deactivation may appear intuitively 373 
surprising and in need of replication. Nevertheless, prior research consistently finds that between-374 
group differences during passive-viewing observed with the current paradigm at least partially 375 
reflect anomalous patterns of amygdala deactivation in one or another unique subgroup.
27,31
  376 
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Moreover, prior work demonstrates the importance of happy faces, specifically, as an optimal 377 
comparison condition, while also suggesting that happy faces index reward-related processes 378 
uniquely perturbed in MDD but not anxiety disorders.
27,33 
Finally, despite some divergence 379 
between the current findings and associated hypotheses emerging from prior studies,
27,31,33
 our 380 
findings documenting disorder-related specificity during passive-viewing extend other work. For 381 
example, Thomas et al.
28
 also used passive-viewing, though no other attention manipulation, and 382 
found amygdala hyper-activation in anxious children and amygdala deactivation in MDD 383 
children.  384 
 385 
Shared-Diathesis 386 
 The current study also provides evidence of amygdala perturbations common to both 387 
adolescent MDD and anxiety disorders. These data suggest that at least some adolescent anxiety 388 
disorders share an underlying neural diathesis with adolescent MDD. Importantly, as with 389 
disorder-specificity, disorder-common manifestations occurred to particular face-emotion types, 390 
when viewed in specific attention states. Support for this conclusion again emerges from our 391 
focus on necessarily complex tests of three-way interactions. Thus, both patient groups had 392 
greater amygdala activation than healthy peers only when viewing fearful faces specifically. 393 
These differences occurred particularly when focusing on subjectively-experienced fear, relative 394 
to passively viewing the same fearful faces or relative to viewing happy or neutral faces in 395 
various attention states. Prior research
27,31
 had led us to expect amygdala perturbations in anxiety 396 
patients specifically when viewing fear-faces and rating fear; the current study extends this 397 
observation to MDD, with or without anxiety.  398 
 Findings from our secondary analyses in the lateral OFC also provide some support for 399 
both the “disorder-specificity” and the “shared-diathesis” perspectives. This pattern is consistent 400 
with prior work implicating a distributed neural circuitry devoted to emotional modulation of 401 
perception and behavior.
27,52-55
  Taken together, findings suggest that adolescent anxiety disorders 402 
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and MDD can exhibit neural commonalities but also distinctions, depending on the specific 403 
attention and emotion states engaged.  404 
 405 
Development 406 
 Common and specific neural perturbations were not affected by sex and age. However, 407 
the current study was not specifically designed to examine questions of sex and age-specificity 408 
across adolescence and adulthood, questions which require large samples of adolescents and 409 
adults. Prior research does indicate differences in patterns of neural responses under varying 410 
emotion/attention conditions between healthy adolescents and adults, though no prior work has 411 
directly compared samples of MDD or anxious and healthy adolescents and adults.
38,56,57
  The 412 
current work now sets the stage for such large, comparative studies among adolescents and adults 413 
with anxiety and mood disorders. Studies directly comparing these groups are needed, given the 414 
demonstrated effects of subtle task variations on between-group differences. Such studies, which 415 
may reveal similar or unique functional perturbations across pathologies and age groups, are 416 
particularly important in light of improved etiological/pathogenic models and treatment options.
58
 417 
  418 
Behavioral Data  419 
 In addition to the fMRI results, we found expected variations in task performance as a 420 
function of attention-condition and face-emotion type, as shown previously.
27,31,32,38
 However, 421 
groups did not differ on task performance. Thus, the current paper, when combined with others 422 
on amygdala function in both adults and adolescents
27,31,33,59
 firmly establishes the fact that 423 
between-group differences in amygdala function emerge even in the absence of between-group 424 
differences in task performance. The observed amygdala differences in the current study 425 
specifically were independent of rated anxiety and are not epiphenomena of between-group 426 
differences in experienced anxiety or other task-performance differences. Some research, 427 
however, suggests that differences in task performance facilitate interpretation of differences in 428 
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neural activation.
60
 From this perspective, the failure of a task to elicit expected between-group 429 
differences in behavior might suggest that the underlying psychological process engaged by the 430 
task is not directly relevant for the condition being studied.  431 
 In the current paper, the failure to observe between-group differences in behaviour, in the 432 
context of between-group differences in neural response, emerges for a task that is clearly 433 
disorder-relevant. Disorder-relevance reflects the definition of clinical anxiety as a condition 434 
characterized by excessive subjectively-reported anxiety. Comparable results emerge in another 435 
study of anxious adolescents,
30
 using another disorder-relevant paradigm that engages threat-436 
attention interactions during orienting, another process previously linked to clinical anxiety. This 437 
study also found between-group differences in the amygdala in the context of no between-group 438 
differences in behaviour. Moreover, the study utilized stimuli presented too rapidly to be 439 
perceived, in terms of their capacity to be rated as elicitors of subjectively-experienced anxiety.  440 
 Taken together, these two studies dissociate individual differences in amygdala function 441 
and individual differences in the subjective experience of anxiety during scanning. Importantly, 442 
though, both studies demonstrate adolescent between-group differences in amygdala function 443 
using tasks previously linked to clinical anxiety. The current report specifically shows that 444 
between-group differences occur specifically during subjective-fear monitoring, the most 445 
clinically-relevant attention state engaged in the current study, but not in other attention states.    446 
  447 
Limitations 448 
 Our findings must be viewed in light of four limitations. First, results are based on small 449 
sample-sizes. Because anxiety and MDD frequently co-occurs, it is difficult to gather large, non-450 
comorbid samples. As a result, true positive effects might have been obscured. Given that type-II-451 
error is more likely than type-I-error with small sample-sizes, negative findings should be 452 
interpreted with more caution than positive findings.   453 
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 Second, additional aspects of our sample complicate interpretations. For example, 454 
findings emerging from analyses that included patients with comorbid MDD/anxiety raise the 455 
question of the degree to which anxiety-comorbidity influences or changes biased neural 456 
engagement in MDD, and whether findings can be attributed to MDD per se. It was not feasible 457 
to recruit sufficiently large samples of subjects in four mutually exclusive groups (MDD alone, 458 
anxiety alone, comorbid MDD/anxiety, and healthy controls). Similar concerns prevented us from 459 
recruiting sufficiently large samples of adolescents with specific anxiety disorders. However, we 460 
repeated all analyses with comorbid patients excluded from the MDD group; these analyses 461 
supported conclusions emerging from other analyses. Yet, some unanswered questions remain as 462 
our adolescent participants with “pure” anxiety or “pure” depression may develop heterotypic 463 
comorbidity in the future. Longitudinal studies conducting serial fMRI assessments might 464 
provide more definitive insights on the developmental trajectories of emerging comorbidity 465 
patterns. Similarly, because comorbidity among the anxiety disorders also complicates 466 
interpretations, future studies should examine brain imaging data in “pure” anxiety groups. 467 
However, such studies will face the problem that few cases with anxiety occur in the absence of 468 
comorbidity and that such samples may be unrepresentative, particularly of cases typically seen 469 
in clinical settings.   470 
 Third, our analysis is limited to amygdala and OFC regions, which may be perceived as a 471 
restricted view of (neural) dysfunction in anxiety and depressive disorders.  472 
 Fourth, the cognitive task used has advantages and disadvantages. Regarding advantages, 473 
prior work suggests that the task elicits disorder-specific profiles
27,31,33,42
 Moreover, the task 474 
explicitly assesses neural activity engaged when participants report distress (i.e., experienced 475 
internal fear), a defining feature of anxiety disorders. On the other hand, ratings of distress 476 
engage a series of complex incompletely-specified psychological processes that require 477 
introspection and can be directed towards various environmental features. Because fearful faces 478 
signal threat but are not directly threatening, a task focusing attention on more general aspects of 479 
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threat might generate unique findings. Furthermore, in the passive-viewing condition, no 480 
information is generated concerning the cognitive processes engaged in each group. The use of 481 
only eight specific emotion events in each attention condition is also a limitation, as tasks with 482 
more replicates posses greater statistical power.
61
 However, as the current analyses attempted to 483 
reveal between-group differences as a function of different emotion and attention conditions, we 484 
needed considerable variation on both factors. In an adolescent sample, for practicability reasons, 485 
this resulted in relatively few specific emotion events in each attention condition, to minimize 486 
task duration. Finally, this concern probably relates more to instances where studies fail to detect 487 
hypothesized between-group differences than to studies such as ours that confirm hypothesized 488 
differences. Thus, while the current paradigm appears to be sensitive to both commonalities and 489 
differences in the neural correlates of adolescent MDD and anxiety disorders, further refined 490 
tasks may generate more precise conclusions concerning the nature of these commonalities and 491 
differences. 492 
 493 
494 
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FIGURE LEGENDS 687 
 688 
Figure 1. Amygdala activation to fearful-faces in anxiety and MDD patients relative to healthy 689 
controls for select attention-conditions. 690 
a. Bar graphs of left amygdala activation to fearful-faces relative to fixation (error bars reflect 691 
standard errors) displaying the group [healthy controls, MDD (with and without anxiety 692 
disorder), anxiety disorder alone]-by-attention-condition interaction. A similar activation pattern 693 
was found for the right amygdala and when excluding comorbid MDD/anxiety patients (not 694 
shown in Figure). 695 
b and c. Bar graphs of left amygdala activation to fearful-faces during afraid-ratings versus 696 
passive-viewing (“fearful-afraid-vs.-fearful-passive” contrast) showing significantly enhanced 697 
activation among both anxiety patients and MDD patients (MDD with and without anxiety 698 
disorder (b.), MDD alone (c.)) compared to healthy controls, with no difference between anxiety 699 
and MDD patients.  700 
d and e. The “fearful-afraid-vs.-fearful-passive” contrast evidences significantly greater left 701 
amygdala activation in (d.) anxiety alone patients compared to controls (Montreal Neurological 702 
Institute (MNI) coordinates: -20, -2, -20, p=.001 (shown in figure); -10, -4, -16, p=.002; MNI 703 
coordinates are small volume corrected (svc)) and (e.) MDD alone patients compared to controls 704 
(MNI coordinates: -20, 4, -16, p=.007; svc). Highlighted areas indicate regions where the 705 
differences in BOLD activation between groups were significant (for displaying purposes, 706 
uncorrected threshold was set at p=.0005 (d.) and p=.005 (e.)). 707 
708 
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Figure 2. Differential amygdala activation in MDD and anxiety patients during passive-viewing 709 
of fearful versus other face-emotion types. 710 
a. Bar graphs of left amygdala activation to passively-viewed facial expressions relative to 711 
fixation (error bars reflect standard errors) among patients with MDD (with and without 712 
comorbid anxiety disorder), patients with anxiety disorder, and healthy controls displaying the 713 
group-by-face-emotion interaction in the passive-viewing condition. A similar activation pattern 714 
was found for the right amygdala and when excluding comorbid MDD/anxiety patients (not 715 
shown in Figure). 716 
b and c. Anxiety patients and MDD patients (with and without comorbid anxiety (b.), MDD alone 717 
(c.)) showed opposite and significantly different left amygdala responses to fearful faces vs. 718 
happy faces passively viewed (“fearful-passive-vs.-happy-passive” contrast). MDD patients and 719 
anxiety patients each also differed from healthy controls in left amygdala activation in this 720 
contrast. 721 
d. The “fearful-passive-vs.-happy-passive” contrast evidences significantly greater left and right 722 
amygdala activation in anxiety patients as compared to MDD patients even when MDD patients 723 
with comorbid anxiety are excluded (MNI coordinates left: -16, 2, -16, p=.014, svc; MNI 724 
coordinates right: 22, 0, -14, p=.001, svc). Highlighted areas indicate regions where the 725 
differences in BOLD activation between groups were significant (for displaying purposes, 726 
uncorrected threshold was set at p=.005). 727 
728 
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Figure 3. OFC activation in the “fearful-afraid-vs.-fearful-passive contrast”. 729 
a and b. Bar graphs of left OFC activation to fearful-faces during afraid-ratings versus passive-730 
viewing (“fearful-afraid-vs.-fearful-passive” contrast) showing significantly enhanced activation 731 
among anxiety patients compared to healthy controls.  732 
c. The “fearful-afraid-vs.-fearful-passive” contrast evidences significantly greater lateral OFC 733 
activation in anxiety patients compared to controls (MNI coordinates left: -50, 22, -2, p=.046 734 
(shown in Figure), -14, 18, -10, p=.050, svc). Highlighted areas indicate regions where the 735 
differences in BOLD activation between groups were significant (for displaying purposes, 736 
uncorrected threshold was set at p=.005). 737 
738 
  
31 
Figure 4. OFC activation in the “fearful-passive-vs.-happy-passive” contrast. 739 
a and b. Bar graphs of right OFC activation to fearful-faces during passive viewing of fearful vs. 740 
happy faces “fearful-passive-vs.-happy-passive” contrast) showing significantly enhanced 741 
activation among anxiety patients compared to MDD patients and compared to healthy controls.  742 
c. The “fearful-passive-vs.-happy-passive” contrast evidences significantly greater right lateral 743 
OFC activation in anxiety patients as compared to MDD patients (with and without comorbid 744 
anxiety: MNI coordinates: 32, 24, -18, p=.005, svc; no suprathreshold voxels emerge for the 745 
anxiety versus MDD alone comparison). Highlighted areas indicate regions where the differences 746 
in BOLD activation between groups were significant (for displaying purposes, uncorrected 747 
threshold was set at p=.0005).  748 
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  753 
Table 1. Demographic and clinical characteristics of subjects with MDD, anxiety disorder and no 754 
psychopathology  755 
                      
Measure 
Healthy 
Controls  
(n = 45) 
MDD with and 
without anxiety 
disorder  
(n= 26) 
MDD without 
anxiety 
disorder  
(n=12) 
Anxiety 
disorder 
without MDD  
(n = 16) 
Age, mean (SD), y 13.93 (2.18) 14.08 (2.23) 14.20 (2.60) 12.77 (1.85) 
IQ, mean (SD) 111.62 (13.57) 110.38 (18.05) 113.5 (21.82) 112.14 (14.53) 
SES, mean (SD) 1 52.00 (23.34) 46.14 (19.34) 42.1 (22.35) 46.92 (24.62) 
Female sex, No. (%) 24 (53) 15 (58) 7 (58) 5 (31) 
DSM-IV diagnoses (current), No. (%)         
 MDD 0  26 (100) 12 (100) 0  
 Any anxiety disorder 0  14 (54) 0  16 (100) 
  GAD 0  10 (39) 0  8 (50) 
  Social Phobia 0  8 (31) 0  5 (31) 
  SAD 0  7 (27) 0  8 (50) 
  GAD alone 0  3 (12) 0  4 (25) 
  Social Phobia alone 0  1 (4) 0  3 (19) 
  SAD alone 0  2 (8) 0  4 (25) 
Pediatric Anxiety Rating Scale (PARS), mean (SD) n/a  15.32 (5.00) 13.42 (4.76) 16.44 (2.50) 
Children's Depression Rating Scale (CDRS), mean (SD) 42.17 (8.43) 59.12 (13.00) 55.55 (13.40) 46.86 (4.45) 
Clinical Global Impressions Scale (CGI), mean (SD) n/a  4.73 (0.83) 4.67 (0.89) 4.19 (0.75) 
1 
SES: Socioeconomic Status: Index generated from occupational and educational level of parents (theoretical range 20 - 137), 
higher values indicate higher SES 
MDD - Major Depressive Disorder         
GAD - Generalized Anxiety Disorder         
SAD - Separation Anxiety Disorder         
n/a - not applicable         
 756 
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Table 2. Task performance by group 758 
                
Behavioral Measures 
Healthy controls  
(n = 45) 
MDD  
with and without 
anxiety disorder 
(n = 25) 
Anxiety disorder 
without MDD 
(n = 14) 
Ratings, mean (SD)       
 How hostile - Neutral faces 1.74 (0.61) 1.82 (0.56) 1.86 (0.88) 
 How hostile - Fearful faces  2.04 (0.83) 2.31 (0.89) 2.27 (1.08) 
 How hostile - Angry faces  3.17 (1.01) 3.42 (0.86) 3.34 (0.96) 
 How hostile - Happy faces 1.10 (0.18) 1.33 (0.42) 1.53 (0.71) 
 How afraid - Neutral faces 1.49 (0.64) 1.68 (0.69) 1.69 (0.83) 
 How afraid - Fearful faces  1.83 (0.77) 2.14 (0.99) 1.93 (1.01) 
 How afraid - Angry faces  2.38 (0.99) 2.52 (0.93) 2.76 (1.23) 
 How afraid - Happy faces 1.14 (0.24) 1.35 (0.49) 1.41 (0.64) 
 How wide is the nose - Neutral faces 2.19 (0.58) 2.12 (0.45) 2.16 (0.40) 
 How wide is the nose - Fearful faces 2.17 (0.54) 2.31 (0.62) 2.15 (0.49) 
 How wide is the nose - Angry faces  2.59 (0.65) 2.59 (0.60) 2.77 (0.50) 
 How wide is the nose - Happy faces 2.59 (0.53) 2.69 (0.53) 2.52 (0.48) 
Reaction times (in ms), mean (SD)       
 How hostile - Neutral faces 1820.19 (438.00) 1986.28 (377.51) 1894.08 (469.09) 
 How hostile - Fearful faces  2031.00 (495.40) 2104.97 (398.01) 1923.39 (373.43) 
 How hostile - Angry faces  1964.88 (400.65) 2000.80 (384.47) 2159.22 (445.21) 
 How hostile - Happy faces 1534.44 (351.09) 1656.25 (428.98) 1715.38 (278.31) 
 How afraid - Neutral faces 1692.53 (432.68) 1925.43 (435.90) 1713.75 (390.73) 
 How afraid - Fearful faces  1828.02 (421.88) 1968.81 (370.44) 1853.62 (414.40) 
 How afraid - Angry faces  1983.81 (443.39) 2057.27 (495.37) 2093.40 (564.12) 
 How afraid - Happy faces 1459.04 (370.12) 1732.17 (421.51) 1634.82 (368.52) 
 How wide is the nose - Neutral faces 1823.26 (363.40) 1918.47 (310.54) 2048.53 (308.56) 
 How wide is the nose - Fearful faces 1912.18 (345.08) 1991.08 (316.78) 1955.11 (260.15) 
 How wide is the nose - Angry faces  1971.25 (415.22) 2082.00 (365.71) 2145.36 (308.08) 
  How wide is the nose - Happy faces 1982.59 (394.67) 2111.49 (340.06) 2022.38 (271.16) 
MDD - Major Depressive Disorder (n=14 with anxiety disorder, n=11 without anxiety disorder) 
 759 
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Table 3. Statistical analyses of Regions of Interest (Omnibus repeated-measures ANOVA) 761 
                                  
  Comorbid MDD/anxiety patients included §  Comorbid MDD/anxiety patients excluded & 
  Left Amygdala  Right Amygdala  Left Amygdala  Right Amygdala 
Effect $  F-Value df p-Value   F-Value df p-Value  F-Value df p-Value   F-Value df p-Value 
Main effect                
 group (between subject effect) 0.98 2, 84 .38  1.25 2, 84 .29  0.52 2, 70 .60  1.40 2, 70 .25 
 emotion (within subject effect) 6.49 2.9, 240.1 <.001*  3.34 2.6, 219.2 .03*  4.45 2.8, 194.2 .006*  1.70 2.5, 177.4 .18 
 attention (within subject effect) 7.53 2.8, 238.5 <.001*  0.16 2.8, 236.2 .91  5.66 2.8, 196.1 .001*  0.15 2.6, 185.1 .91 
2-way interaction                
 group by emotion 2.16 5.7, 240.1 .05  1.80 5.2, 219.2 .11  2.02 5.6, 194.2 .07  1.94 5.1, 177.4 .09 
 group by attention 3.00 5.7, 238.5 .009*  0.88 5.6,  236.2 .50  2.74 5.6, 196.1 .02*  0.63 5.3,  185.1 .69 
 emotion by attention 1.21 7.4, 621.1 .30  1.69 6.6, 553.6 .12  1.45 7.2, 505.0 .18  1.31 6.0, 416.6 .25 
3-way interaction                
  group by emotion by attention 2.68 14.8, 621.1 .001*   2.01 13.2, 553.6 .02*   2.71 14.4, 505.0 .001*   1.90 11.9, 416.6 .03* 
§ MDD patients with and without comorbid anxiety disorder (n=26), anxiety patients (n=16), healthy controls (n=45)       
& MDD patients without comorbid anxiety disorder (n=12), anxiety patients (n=16), healthy controls (n=45)         
$ Results of omnibus repeated-measures analyses of variance (Greenhouse-Geisser corrected)          
group: MDD, Anxiety, Controls                
emotion: neutral, fearful, angry, happy               
attention: hostile, afraid, nose, passive               
* significant at P<0.05                
 762 
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